CXCL1 is elevated in the urine of bladder cancer patients

SpringerPlus

Volumn 4, Issue 1, 2015, Pages

  Burnier, Andre ^a   Shimizu, Yoshiko ^b,c   Dai, Yunfeng ^d   Nakashima, Masakazu ^e,f   Matsui, Yoshiyuki ^f   Ogawa, Osamu ^f   Rosser, Charles J ^b   Furuya, Hideki ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e KANSAI ELECTRIC POWER CO   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; CXCL1; Sensitivity; Specificity; Urine

Indexed keywords

EID: 84944451419     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/s40064-015-1393-9     Document Type: Article

References (31)

1. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M (2006) The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 7(9):R80. doi:10.1186/gb-2006-7-9-R80
2. Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis–translation from murine model to clinical trial. Cancer metastasis Rev 26(3–4):623–634. doi:10.1007/s10555-007-9084-9
3. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC, Group S (2004) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 21(1):4–10
4. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Bohle A (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186(6):2158–2167. doi:10.1016/j.juro.2011.07.076
5. Chen LM, Chang M, Dai Y, Chai KX, Dyrskjot L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ (2014) External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 23(9):1804–1812. doi:10.1158/1055-9965.EPI-14-0029
6. Dhawan P, Richmond A (2002) Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 72(1):9–18
7. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33(1):90–96. doi:10.1038/ng1061
8. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acid Res 30(1):207–210
9. Escudero-Lourdes C, Wu T, Camarillo JM, Gandolfi AJ (2012) Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells. Toxicol Appl Pharmacol 258(1):10–18. doi:10.1016/j.taap.2011.10.002
10. Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, Krueger K, Zheng Y, Patriotis C, Huang Y, Sorbara L, Thompson I, Srivastava S (2013) The early detection research network’s specimen reference sets: paving the way for rapid evaluation of potential biomarkers. Clin Chem 59(1):68–74. doi:10.1373/clinchem.2012.185140
11. Gillitzer R, Goebeler M (2001) Chemokines in cutaneous wound healing. J Leukoc Biol 69(4):513–521
12. Hembruff SL, Cheng N (2009) Chemokine signaling in cancer: implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 7(A):254–267
13. Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O (2008) Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res 14(9):2579–2587. doi:10.1158/1078-0432.CCR-07-1922
14. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS (2010) Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol Off J Am Soc Clin Oncol 28(16):2660–2667. doi:10.1200/JCO.2009.25.0977
15. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol Off J Am Soc Clin Oncol 23(24):5746–5756. doi:10.1200/JCO.2005.01.598
16. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I (2008) NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8:41. doi:10.1186/1471-2407-8-41
17. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ (2013) Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer 13:322. doi:10.1186/1471-2407-13-322
18. Nakashima M, Matsui Y, Kobayashi T, Saito R, Hatahira S, Kawakami K, Nakamura E, Nishiyama H, Ogawa O (2015) Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer. Cancer Biomark 15(4):357–364
19. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100(20):1432–1438. doi:10.1093/jnci/djn326
20. Reid CN, Stevenson M, Abogunrin F, Ruddock MW, Emmert-Streib F, Lamont JV, Williamson KE (2012) Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat. PLoS One 7(12):e53354. doi:10.1371/journal.pone.0053354
21. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP, Srougi M, Dall’Oglio MF (2012) Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol 12:18. doi:10.1186/1471-2490-12-18
22. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S (2013) Multiplex protein signature for the detection of bladder cancer in voided urine samples. J urol 190(6):2257–2262. doi:10.1016/j.juro.2013.06.011
23. Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S (2014) Urinary protein biomarker panel for the detection of recurrent bladder cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 23(7):1340–1345. doi:10.1158/1055-9965.EPI-14-0035
24. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62(23):6973–6980
25. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics (2014). CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208
26. Surveillance, Epidemiology, and End Results Program (2013). http://www.seer.cancer.gov/csr/1975_2010/. Accessed 16 Dec 2013
27. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, Chancellor M (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42(3):629–635. doi:10.1007/s11255-009-9647-5
28. Vazquez-Martin A, Colomer R, Menendez JA (2007) Protein array technology to detect HER2 (erbB-2)-induced ‘cytokine signature’ in breast cancer. Eur J Cancer 43(7):1117–1124. doi:10.1016/j.ejca.2007.01.037
29. Verbeke H, Struyf S, Laureys G, Van Damme J (2011) The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 22(5–6):345–358. doi:10.1016/j.cytogfr.2011.09.002
30. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, EuropeanAssociation of U (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. doi:10.1016/j.eururo.2013.11.046
31. Zhao Y, Zhu L, Zhou T, Zhang Q, Shi S, Liu L, Lv J, Zhang H (2015) Urinary CXCL1: a novel predictor of IgA nephropathy progression. PLoS One 10(3):e0119033. doi:10.1371/journal.pone.0119033